Biopiracy — Neem, Turmeric & Basmati Case Studies 🌿
Complete UPSC Notes — What is biopiracy, how it happens, landmark Indian victories (Neem at EPO, Turmeric at USPTO, Basmati vs RiceTec), India's defensive arsenal (TKDL, Biological Diversity Act, Nagoya Protocol, Patents Act), the WIPO Treaty 2024, Biological Diversity Amendment Act 2023, and the broader biopiracy ecosystem — with PYQs, MCQs, case timelines, and memory aids.
🌍 What is Biopiracy? — The Big Picture
💡 The "Library Book" Analogy
Imagine a community library built over centuries — every family in a village contributed books, and everyone uses them freely. Then one day, an outsider walks in, photographs one chapter, registers it as their own "discovery," and starts charging the whole village a fee to access knowledge they created. That is biopiracy. The "library" is traditional knowledge; the "books" are medicinal plants, farming techniques, and genetic resources built up by indigenous communities over millennia. The outsider is a corporation from a wealthy country using the patent system to claim ownership over what was never theirs.
Type 1 — Patenting Traditional Knowledge
Registering what indigenous communities already know — wound-healing by turmeric, antifungal properties of neem — as a novel invention. The knowledge is not new; only the patent is. Examples: Turmeric (1995), Neem (1994, 1995), Hoodia cactus (South Africa).
Type 2 — Patenting Genetic Resources
Collecting plant/animal genetic material from biodiversity-rich countries, using it to develop commercial products (drugs, seeds, cosmetics), and patenting the derived product without benefit-sharing. Example: Basmati rice varieties used by RiceTec to breed new lines.
Type 3 — Misappropriation of GI Products
Using the name or brand of a geographically-linked product (e.g., "Basmati," "Darjeeling Tea") outside the source region, misleading consumers about origin. Overlaps with Geographical Indication (GI) law — India's GI Act 1999 was partly a response to Basmati.
🌿 The Neem Case — World's First Biopiracy Victory
Robert Larson (USDA) Files First Neem Patent
US agronomist Robert Larson obtained a US patent for a neem seed extract preparation. The Environmental Protection Agency (EPA) approved this product for the US market. Larson sold this patent to US company W.R. Grace in 1988 — a major agrochemical multinational. W.R. Grace set up a manufacturing plant in India in collaboration with P.J. Margo Pvt. Ltd.
EPO Grants Patent #436257 to USDA + W.R. Grace
The European Patent Office (EPO) granted patent No. EP 436257 B1 to the US Department of Agriculture (USDA) and W.R. Grace & Company for a fungicidal product derived from seeds of the neem tree — specifically for the hydrophobic extracted neem oil as an antifungal agent. W.R. Grace began marketing this product across the European Union.
Legal Opposition Filed — Vandana Shiva + IFOAM + MEP Aelvoet
A three-party coalition filed a legal opposition at the EPO: Dr. Vandana Shiva's Research Foundation for Science, Technology and Ecology (RFSTE), New Delhi; the International Federation of Organic Agriculture Movements (IFOAM); and Magda Aelvoet, then a Green Member of the European Parliament and later Belgium's Environment Minister. Their joint legal opposition argued that the fungicidal properties of neem had been public knowledge in India for centuries and that the patent exemplified how international law was being misused.
EPO Opposition Division REVOKES the Patent (First Victory)
After a two-day oral hearing at Munich, the EPO's Opposition Division completely revoked EPO patent #436257. Indian expert witness Abhay Phadke — an agronomist who had produced a commercial neem product in India without any patent claim — testified extensively, along with Dr. U.B. Singh. Ancient Indian ayurvedic texts and a 1981 paper by H.B. Singh and U.P. Singh on neem's antifungal properties were presented as prior art. The panel concluded: no inventive step was involved as the claimed invention was already public knowledge in India. USDA and W.R. Grace appealed the decision.
EPO Technical Board of Appeals — FINAL VICTORY (10-Year Battle Ends)
The EPO's Technical Board of Appeals dismissed the appeal by USDA and the company (now named Thermo Trilogy, after W.R. Grace transferred the patent) and upheld the revocation in its entirety. This was the world's first successful legal challenge to a biopiracy patent, described as a "landmark victory" by the Research Foundation. The Board found that prior art — including a 1981 scientific article on neem's antifungal effects — clearly anticipated the patent claims. The 10-year legal battle was over.
1. Lack of novelty (Prior Art): The antifungal use of neem had been documented in Indian agricultural and medical literature for centuries and in scientific publications. The 1981 paper by H.B. Singh and U.P. Singh on neem's antifungal effect on plant pathogens was specifically cited as prior art.
2. No inventive step: The EPO found that deriving a fungicide from neem seeds did not involve any inventive step beyond what was already publicly known. A person skilled in the art would have arrived at the same formulation.
3. Public domain knowledge: The hydrophobic extraction of neem oil and its antifungal properties were part of the public domain — known to Indian farmers, traditional practitioners, and scientists alike.
🌾 The Turmeric Case — India's First USPTO Victory
Patent Application Filed at USPTO
Two scientists of Indian-American origin — Dr. Suman Kumar Das and Dr. Hari Har Parshad Cohly — of the University of Mississippi Medical Center filed a patent application at the USPTO for "the use of turmeric in wound healing." The application covered six claims, including turmeric's use for healing wounds both orally (ingested) and topically (applied externally), and for treating ulcers.
USPTO Grants Patent No. 5,401,504
The United States Patent and Trademark Office granted US Patent No. 5,401,504 to the University of Mississippi Medical Center, covering the method of promoting wound healing using turmeric preparations (oral and topical). This effectively gave the university exclusive rights over the use of turmeric for wound healing — including the right to sell and distribute globally. The patent's grant also implicitly gave them the ability to sue for royalties against any commercial entity using turmeric for wound healing.
CSIR Files Re-examination Request — Armed with 32 Prior Art Documents
The Council of Scientific and Industrial Research (CSIR) of India filed a request for re-examination of the patent at the USPTO. CSIR submitted 32 prior art references in multiple languages — Sanskrit, Urdu, and Hindi — establishing that the wound-healing use of turmeric had been traditional knowledge in India for thousands of years. Key evidence included: ancient Ayurvedic texts (Charaka Samhita, Sushruta Samhita); Sanskrit and Urdu documents describing haldi for skin conditions; and critically, a 1953 paper published in the Journal of the Indian Medical Association — a peer-reviewed scientific publication that explicitly documented turmeric's wound-healing properties. This last reference was decisive — it showed that even in modern scientific literature, turmeric's wound-healing use predated the 1993 patent application.
USPTO Rejects All 6 Claims — Patent Falls on Prior Art
The USPTO non-final office action on re-examination rejected all 6 claims, finding they were anticipated by the prior art submitted by CSIR and hence invalid under 35 USC §102(a) (novelty requirement). The inventors argued that turmeric powder and paste were different — and that the patent specifically covered powder. The USPTO rejected this distinction, finding that a person of ordinary skill in the art (PHOSITA test) would consider them equivalent for wound-healing purposes. Claims were also rejected on grounds of obviousness.
Patent REVOKED — India's First USPTO Victory Against Biopiracy
The USPTO issued its order on November 20, 1997, revoking the patent on grounds of it being obvious and anticipated by prior art. The re-examination certificate (issued in 1998) formally ended the case. CSIR's 32 prior art documents had proved beyond any question that turmeric's wound-healing use was not a discovery — it was millennia-old Indian traditional knowledge. The case cost India approximately $2 million in legal costs — a high price that demonstrated the need for a more proactive, cheaper mechanism to protect traditional knowledge: the TKDL.
1. Lack of novelty / Prior art (35 USC §102): The wound-healing use of turmeric was not novel — it was already known and published. The 1953 paper in the Journal of the Indian Medical Association was a peer-reviewed scientific publication (not just oral tradition) that the examiner could not ignore.
2. Obviousness (35 USC §103): Even if the exact application was not published, it would have been obvious to any person skilled in the art given the extensive traditional use.
3. PHOSITA equivalence: The USPTO held that turmeric powder and paste were equivalent for healing purposes — defeating the inventors' main defence that they had patented a specific form. This was India's first-ever successful challenge to a US patent based on traditional knowledge.
🍚 The Basmati Case — Protecting a Geographical Heritage
RiceTec Inc. (Texas) Granted US Patent #5,663,484
RiceTec Inc., a private Texas-based company owned by Prince Hans-Adam II of Liechtenstein, was granted US Patent No. 5,663,484 — titled "Basmati Rice Lines and Grains" — by the USPTO. The patent covered: new rice varieties (Bas 867, RT1117, RT1121) developed by crossing long-grain and semi-dwarf rice with 22 Indian and Pakistani basmati varieties; a method of selecting rice plants for basmati aroma, elongation, and texture; and the use of the term "basmati" for varieties grown in the Western Hemisphere and Caribbean. RiceTec marketed its products under names "Texmati," "Kasmati," and "Jasmati." India's annual basmati exports were worth billions — this patent directly threatened them.
Global Outcry — India, Pakistan, and Civil Society Unite
The patent provoked outrage in India and Pakistan, and among a worldwide coalition of 90 civil society organisations. India's Research Foundation for Science, Technology and Ecology (Vandana Shiva) condemned it as "biopiracy." APEDA (Agricultural & Processed Food Products Export Development Authority) prepared up to 50,000 pages of documentary evidence establishing basmati's Indian origin. Farmers across South Asia protested. The Indian government formally challenged the patent through APEDA.
RiceTec Voluntarily Withdraws 4 Claims Under Pressure
Under the pressure of international protest and India's formal challenge, RiceTec voluntarily withdrew 4 of the 20 patent claims in June 2000. The USPTO accepted India's petition for re-examination. The USPTO judged that the rice lines RiceTec claimed were substantially identical to existing Indian and Pakistani basmati varieties — they were "prior art" and could not be independently patented.
RiceTec Withdraws 15 of 20 Claims — India Declares Victory
After the 3-year legal battle, RiceTec withdrew 15 of the 20 patent claims. Crucially, the USPTO required the patent title to be changed from "Basmati Rice Lines and Grains" to "Rice Lines Bas 867, RT1117 and RT1121" — removing the word "Basmati" entirely. The word "Basmati" could no longer appear in the patent title. The 3 most important claims (15–17) were annulled. India declared victory. The outcome was pivotal: it galvanised India to introduce the Geographical Indications of Goods (Registration and Protection) Act, 1999 (which had actually been notified in 1999 as part of TRIPS compliance), giving legal protection to products with specific geographic origin.
📊 Three Cases Side by Side — Full Comparison Table
| Parameter | 🌿 Neem | 🌾 Turmeric | 🍚 Basmati |
|---|---|---|---|
| Patent Holder | USDA + W.R. Grace & Co. (US multinational) | University of Mississippi Medical Center (US public university) | RiceTec Inc. (Texas; owned by Prince of Liechtenstein) |
| Patent Office | European Patent Office (EPO), Munich | US Patent and Trademark Office (USPTO) | USPTO |
| Patent Number | EP 436257 B1 | US 5,401,504 | US 5,663,484 |
| Year Granted | 1994 (EPO) | March 28, 1995 | September 1997 |
| What Was Claimed | Fungicidal product from neem seed (antifungal use of hydrophobic neem oil extract) | Method of promoting wound healing using turmeric — oral and topical | New rice lines + basmati aroma/elongation properties + use of the term "Basmati" in W. Hemisphere |
| Type of Biopiracy | Patenting traditional knowledge (antifungal use was centuries-old Indian knowledge) | Patenting traditional knowledge (wound healing by turmeric = ancient Indian practice) | Patenting genetic resources + misuse of geographical brand name |
| Who Challenged | Vandana Shiva (RFSTE) + IFOAM + MEP Magda Aelvoet | CSIR (Council of Scientific and Industrial Research, India) | Government of India through APEDA + civil society coalition of 90 organisations |
| Evidence / Prior Art | Ancient Ayurvedic texts; 1981 paper by H.B. Singh & U.P. Singh on neem's antifungal effect; testimony of Abhay Phadke (commercial neem producer) | 32 prior art documents in Sanskrit, Urdu, Hindi; 1953 paper in Journal of Indian Medical Association; Charaka Samhita | 50,000 pages of evidence establishing basmati's Indian/Pakistani origin; 27 Indian + 22 Pakistani existing basmati varieties |
| Outcome | FULL REVOCATION — 2005 | FULL REVOCATION — 1997 | 15/20 CLAIMS WITHDRAWN — 2002; "Basmati" removed from title |
| Final Date | March 8, 2005 (EPO Appeals upheld revocation) | November 20, 1997 (order); 1998 (re-examination certificate) | January 29, 2002 (RiceTec withdrew 15 claims) |
| Key Legal Ground | No novelty + no inventive step (prior art in scientific literature) | No novelty + obviousness (prior art in ancient texts + 1953 Journal paper) | Prior art — existing Indian/Pakistani basmati varieties anticipated RiceTec's claims |
| Lasting Impact on India | Catalysed TKDL; first EPO reversal based on TK; global precedent | Directly triggered TKDL creation; showed need for proactive TK documentation | Triggered GI Act 1999; accelerated TKDL; global awareness of biopiracy |
🛡️ India's Anti-Biopiracy Arsenal — Complete Framework
🗄️ A. TKDL — Traditional Knowledge Digital Library (2001)
The TKDL was established in 2001 as a collaborative initiative of the Council of Scientific and Industrial Research (CSIR) and the then-Ministry of Health and Family Welfare (now Ministry of AYUSH). It is the world's first and most comprehensive digital repository of traditional medicinal knowledge, designed specifically to function as prior art before patent offices worldwide.
• 5.15 lakh (515,000+) formulations and practices transcribed and structured
• Covers: Ayurveda, Unani, Siddha, Sowa Rigpa, and Yoga
• Structured as 34 million A4-sized pages in patent application format
• Translated into 5 languages: English, French, German, Japanese, Spanish
• Based on 148 books of ISM in the public domain
• Uses TKRC (Traditional Knowledge Resource Classification) — a unique classification system that maps traditional knowledge to International Patent Classification codes
• 375+ patent applications blocked (rejected/withdrawn/amended/abandoned) globally as of latest data
• In Europe alone, within 2 years of launch: 36 applications cancelled or withdrawn
• Signed access agreements with EPO, USPTO, UKIPO, Japan Patent Office, CIPO (Canada) and others
• Cost per patent challenge through TKDL: near zero (vs. ~$2 million for turmeric case)
• Criteria: "2,000 patents based on India's TK being granted annually" (expert group, ~2000) — TKDL aimed to stop this at the source
🌱 B. Biological Diversity Act 2002 + Amendment 2023 + Rules 2024
India enacted the Biological Diversity Act (BDA), 2002 to implement its obligations under the Convention on Biological Diversity (CBD, 1992). The Act established a three-tier regulatory framework: NBA (National Biodiversity Authority) at the centre, State Biodiversity Boards (SBBs) at the state level, and Biodiversity Management Committees (BMCs) at the local/panchayat level. Key provisions of the original Act: mandatory prior approval of NBA for foreign entities accessing Indian biological resources; mandatory NBA approval before filing IPR on biological resources from India; benefit-sharing obligations.
• Decriminalised offences — shifted from imprisonment to financial penalties (₹1 lakh to ₹50 lakh)
• Eased compliance for Indian entities — Indian nationals/companies need only register with NBA (not get prior approval) for accessing bio-resources for research; prior approval needed only for commercial use
• Foreign entities still need prior NBA approval for all stages
• DSI (Digital Sequence Information) — now included within the Act's purview; addresses a growing loophole
• Biological Diversity Rules 2024 notified October 22, 2024 (effective December 22, 2024) — replace 2004 Rules; online application portal, defined timelines, revised fees
⚠️ Critics: The 2023 amendment eases compliance for industry but may weaken community protections. Indigenous representatives and Ministry of Tribal Affairs opposed certain relaxations as prioritising corporate profits over community rights.
⚖️ C. Patents Act 1970 (Amended 2005) — Anti-Biopiracy Provisions
Inventions whose "primary or intended use or commercial exploitation would be contrary to public order or morality or which causes serious prejudice to human, animal or plant life or health or to the environment" are NOT patentable. Used to block patents that would harm biodiversity or exploit communities.
"Plants and animals in whole or any part thereof other than micro-organisms but including seeds, varieties and species and essentially biological processes for production or propagation of plants and animals" are NOT patentable. Directly prevents patenting of basmati rice varieties or neem tree per se.
Inventions that are "an aggregation or duplication of known properties of traditionally known component or components" are NOT patentable. This directly prevents patenting of traditional knowledge — the turmeric wound-healing use would be rejected under this section in India.
Patent applicants in India must disclose whether the invention uses or is based on biological resources or traditional knowledge, and must obtain NBA approval if so. Non-disclosure is an offence. This addresses the core biopiracy mechanism — undisclosed use of Indian resources.
🌐 D. Nagoya Protocol (2010) — Ratified by India 2014
The Nagoya Protocol on Access and Benefit-Sharing (ABS) was adopted under the Convention on Biological Diversity (CBD) in Nagoya, Japan in 2010. India ratified it in 2014. Core requirements: Prior Informed Consent (PIC) from the provider country before accessing genetic resources; Mutually Agreed Terms (MAT) for any access; fair and equitable benefit-sharing of profits derived from using the resources. Implemented in India through Biological Diversity Act 2002 + ABS Rules 2014. India's NBA is the Competent National Authority under the Nagoya Protocol. Key limitation: Nagoya Protocol does not apply retroactively to resources accessed before 2010.
🏷️ E. Geographical Indications Act 1999
Enacted in 1999 under TRIPS obligations (Article 22–24), partly triggered by the Basmati controversy. GI protection links a product's quality and reputation to its geographic origin. GI-tagged Indian products: Darjeeling Tea, Kanchipuram Silk, Alphonso Mango, Tirupati Laddu, Mysore Agarbatti, Basmati Rice (2023). India registered basmati rice as a GI in India in 2023 — a long-overdue step. GI protections are enforced by the Geographical Indications Registry, Chennai. A GI tag does not prevent foreign companies from using the name everywhere globally (unlike a patent) — multilateral recognition requires WTO negotiations, which remain ongoing.
📊 Key Facts and Statistics for UPSC
• Hoodia Cactus (South Africa): San indigenous people of Kalahari used Hoodia to suppress hunger on long hunts. Unilever obtained a patent; eventually signed a benefit-sharing agreement with the San — a rare case of compensation.
• Ayahuasca (Amazon): A US citizen patented the ayahuasca vine (Banisteriopsis caapi) in 1986 — considered sacred by Amazonian indigenous peoples. The patent was challenged and rejected in 1999 (re-examination), though appeals continued.
• Quinoa (Bolivia/Peru): US patent on sterile hybrid quinoa plants was granted; Bolivia and Peru objected on grounds of traditional farmer varieties; the patent was later abandoned.
• Yoga (India): Over 900 yoga-related patents have been filed globally, mostly by US entities. India's TKDL expanded to include Yoga formulations. India successfully opposed several yoga-related patents at the USPTO through TKDL.
📰 Current Affairs 2023–2026 (Fact-Verified)
🗞️ High-Priority News for UPSC 2026
📜 Previous Year Questions (PYQs)
🎯 UPSC PYQs — Biopiracy, TK, and Biodiversity
1. TKDL is a database of traditional knowledge, including Ayurveda, Yoga, Unani and Siddha.
2. The database contains formulations of various herbal medicines, which are publicly available on the internet.
Which of the statements given above is/are correct?
(a) 1 only (b) 2 only (c) Both 1 and 2 (d) Neither 1 nor 2
Answer: (a) — 1 only. Statement 1 ✓ — TKDL covers Ayurveda, Unani, Siddha, Yoga (and now Sowa Rigpa). Statement 2 ✗ — TKDL is NOT publicly available on the internet. It is accessible only to patent examiners of signatory patent offices under strict access agreements (NDAs) — patent examiners can use it for search/examination purposes only and cannot share contents with third parties. Making it publicly accessible is a debated limitation of the TKDL model.
1. It is under the administrative control of the Ministry of Science and Technology.
2. It is a repository of traditional knowledge available in local and foreign languages.
Which is/are correct?
(a) 1 only (b) 2 only (c) Both 1 and 2 (d) Neither 1 nor 2
Answer: (d) — Neither. Statement 1 ✗ — TKDL is a joint initiative of CSIR (under Ministry of Science & Technology) and the then-Ministry of Health and Family Welfare. CSIR alone is not the administrative authority; it is co-administered with AYUSH. Statement 2 ✗ — TKDL translates ancient Indian knowledge (Sanskrit, Arabic, Persian, Urdu, Tamil) into international languages (English, French, German, Japanese, Spanish) — not into "local and foreign languages" as stated. The direction is from local to international, not both ways. This is a precise UPSC distinction.
Key distinction: Cartagena Protocol (2000) — deals with safe transfer, handling, and use of Living Modified Organisms (LMOs, i.e., GMOs) across borders; focuses on environmental safety (biosafety). Adopted under CBD. India is a party. Nagoya Protocol (2010) — deals with Access and Benefit-Sharing (ABS) for genetic resources and associated traditional knowledge; aims to prevent biopiracy and ensure fair compensation to source communities. Also adopted under CBD. India ratified 2014. Challenges: Lack of clear legal frameworks for TK protection; difficulty in defining "traditional knowledge" (codified vs. uncodified, individual vs. community); monitoring use of GRs once accessed abroad; capacity gaps in developing countries for legal enforcement; digital sequence information (DSI) exemption gap; retroactivity problem (resources accessed before 2010 not covered).
Key points: Genetic resources = biological material from plants, animals, microbes with actual or potential value. Traditional knowledge = knowledge, innovations, and practices of indigenous communities developed over generations. Three CBD objectives: conservation, sustainable use, ABS. Biopiracy examples: Neem (USDA/Grace), Turmeric (Univ. of Mississippi), Basmati (RiceTec), Hoodia (Unilever). Nagoya Protocol: PIC requirement, MAT, national checkpoints, international ABS compliance certificate, Benefit Sharing Fund. India's implementation: BDA 2002 + Amendment 2023 + ABS Rules 2014 + NBA as Competent National Authority. TKDL as defensive protection. Challenges: DSI gap, retroactivity, enforcement across jurisdictions, WTO TRIPS-CBD conflict.
Answer framework: Define biopiracy (Pat Mooney, 1993); explain mechanism (patent + traditional knowledge + genetic resources + no benefit sharing); give examples: Neem (EPO), Turmeric (USPTO), Basmati (USPTO), Hoodia, Ayahuasca; effects on developing nations: economic loss (royalties, export competition), cultural appropriation, threat to food security (monopoly on seeds), loss of biodiversity as communities lose incentive to conserve, undermining of IPR legitimacy, denial of health benefits to local communities; India's response: BDA 2002 + Amendment 2023, TKDL 2001, Nagoya Protocol 2014, Patents Act Section 3(j)(p), GI Act 1999, WIPO Treaty 2024.
📝 UPSC-Style MCQs — Test Yourself
1. TKDL was established in 2001 by CSIR and the then-Ministry of Health and Family Welfare.
2. The database is available to the general public on the internet for free access.
3. Patent examiners at signatory offices can use TKDL as prior art to reject patent applications.
4. TKDL covers formulations from Ayurveda, Unani, Siddha, Sowa Rigpa, and Yoga.
Select the correct answer:
1. RiceTec was a Texas-based company that patented Basmati rice lines and grains in 1997 (US Patent 5,663,484).
2. India challenged this at the EPO (European Patent Office).
3. RiceTec agreed to withdraw 15 out of 20 patent claims by 2002.
4. The patent title was changed to remove the word "Basmati."
Which statements are correct?
🧠 Memory Aid — Lock These In for Prelims Day
🔑 Biopiracy — All Critical Facts for UPSC
❓ FAQs — Concept Clarity
Why could foreign entities patent Indian traditional knowledge — wasn't that knowledge already in the public domain?
Did the neem patent revocation mean W.R. Grace could not sell neem products in Europe?
Is TKDL's closed-access model a limitation? Should it be made public?
How does the GI Act differ from the TKDL in protecting traditional products?
What is "Digital Sequence Information" (DSI) and why is it a new biopiracy concern?
🏁 Conclusion — UPSC Synthesis
🌿 From Village Pharmacy to International Courts — The Long Battle
The neem tree did not need a patent to be useful — it had been healing Indian villages for 2,000 years before W.R. Grace arrived. Turmeric did not need a university laboratory to discover its wound-healing properties — every Indian mother knew. The farmers of Punjab and Haryana did not need a Texas company to tell them basmati was special — they had bred its distinctive aroma and texture over generations. What these communities did need was a system that recognised their knowledge as prior art, their genetic resources as sovereign assets, and their traditional innovations as worthy of legal protection.
India's battles against biopiracy — fought through years of expensive legal proceedings, mountains of documentary evidence, and the intellectual work of scientists and activists — eventually gave the world something more valuable than any individual patent victory: the TKDL, a model for how developing nations can use digital documentation to protect traditional knowledge at negligible cost. Where the turmeric case cost India $2 million, TKDL now blocks patents at essentially zero direct cost. Where ancient texts were once inaccessible to foreign patent examiners, they are now just a database query away. The May 2024 WIPO Treaty builds on this work — imperfect, but a step toward a more equitable global IP system.
For UPSC Prelims: Turmeric patent = US 5,401,504 (Univ. of Mississippi, 1995, revoked 1997 by CSIR, 32 prior art docs, 1953 JMA paper); Neem = EPO 436257 (USDA + W.R. Grace, 1994, revoked 2000 EPO Opposition + upheld 2005 EPO Appeals — world's first biopiracy reversal, Vandana Shiva); Basmati = US 5,663,484 (RiceTec, 1997, 15/20 claims withdrawn 2002, USPTO — NOT EPO, triggered GI Act 1999); TKDL = 2001, CSIR + AYUSH, NOT public, 5.15L formulations, 375+ patents blocked; BD Amendment Act 2023 in force April 1, 2024; WIPO GR&TK Treaty = May 24, 2024 (27th WIPO treaty, disclosure requirement, 15 ratifications needed); Nagoya ≠ Cartagena; Pat Mooney coined biopiracy (1993).
For Mains: Always link to CBD (1992) + Nagoya Protocol (2010, ratified India 2014) + TRIPS + GI Act + BDA 2002 + Patents Act Sections 3(j)(p)(b). Use Neem, Turmeric, Basmati as case studies. Discuss DSI as emerging challenge. Evaluate TKDL's limitations (not public, gaps in enforcement globally). Connect to North-South IP divide and India's leadership in pushing for equitable global IP norms.
